The following disclosures belong to interviewees in the CLN article, "Tools for Combatting a Silent Epidemic," published in the May 2019 issue.
Loomba is a consultant for Siemens.
Neuschwander-Tetri has consulting and/or advising relationships with Allergan, Arrowhead, Blade, Boehringer Ingleheim, BMS, Coherus, Consynance, Durect, Enanta, Gelesis, Gilead, Intercept, Lipocine, Madrigal, Medimmune, Merck, Metacrine, NGM, pH-Pharma, Prometheus, Siemens
Rinella has consulting, educating, and/or advising relationship with Enanta Pharmaceuticals, Inc., Fishawack Communications, Focus Medical Communications, LLC, Gilead Sciences, Inc., Huron Consulting Group, Inc., Indiana University, Integritas Communications, Intercept Pharmaceuticals, Inc., KL Logistics, NGM Biopharmaceuticals, Inc., Novartis, NuSirt Biopharma, Pfizer, Inc., SC Liver Research Consortium, LLC, Symbiotix.
Scott L. Friedman, M.D. – Disclosures, February 2019
| Company |
Clinical Area |
Approved Drug/Device |
|
Abide Therapeutics
|
NASH therapeutics
|
None
|
|
Allergan Pharmaceuticals
|
NASH therapeutics
|
None
|
|
Angion Biomedica
|
Fibrosis therapeutics
|
None
|
|
Blade Therapeutics
|
Fibrosis therapeutics
|
None
|
|
Can-Fite Biopharma
|
Liver cancer therapeutics
|
None
|
|
Enanta Pharmaceuticals
|
NASH therapeutics
|
None
|
|
Escient Therapeutics
|
Liver Therapeutics
|
None
|
|
Forbion
|
NASH therapeutics
|
None
|
|
Galmed
|
NASH therapeutics
|
None
|
|
Genfit
|
NASH therapeutics
|
None
|
|
Glycotest
|
Liver cancer diagnostics
|
None
|
|
Glympse Bio
|
Liver fibrosis diagnostics
|
None
|
|
Metacrine Inc.
|
NASH therapeutics
|
None
|
|
Mistral Biosciences
|
NASH therapeutics
|
None
|
|
Morphic Rock Therapeutics
|
Fibrosis therapeutics
|
None
|
|
North Sea Therapeutics
|
NASH therapeutics
|
None
|
|
Novartis
|
NASH therapeutics
|
None
|
|
Novo Nordisk
|
NASH therapeutics
|
None
|
|
Pfizer Pharmaceuticals
|
Fibrosis therapeutics
|
None
|
|
Salix Pharmaceuticals
|
NASH therapeutics
|
None
|
|
Scholar Rock
|
Fibrosis therapeutics
|
None
|
|
Seal Rock Therapeutics
|
NASH therapeutics
|
None
|
|
Second Genome
|
NASH therapeutics
|
None
|
|
Surrozen
|
Liver therapeutics
|
None
|
|
Symic Bio
|
NASH therapeutics
|
None
|
|
Viking Therapeutics
|
Fibrosis therapeutics
|
None
|
|
Kintai
|
NASH therapeutics
|
None
|
Stock Options (all less than 1% of company value):
- Akarna Therapeutics
- BirdRock Bio
- Blade Therapeutics
- Conatus
- DeuteRx
- Exalenz
- Galectin
- Galmed
- Genfit
- Glympse
- Intercept
- Jecure Therapeutics
- Lifemax
- Nimbus
- Northern Biologics
- Scholar Rock
- Tobira Therapeutics
Research Contracts (Cell culture or animal studies)
- Blade Therapeutics
- Can-Fite Biopharma
- Ferring Research Institute.
- Galmed
Stock Ownership
- Intercept
- Exalenz
- Madrigal